Operaciones Johnson & Johnson - JNJ CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Condiciones de trading
| Diferencial | 0.53 | ||||||||
|
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.024068% | ||||||||
|
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.001846% | ||||||||
| Horario tarifa nocturna | 21:00 (UTC) | ||||||||
| Cantidad comercializada mínima | 1 | ||||||||
| Divisa | USD | ||||||||
| Margen | 20% | ||||||||
| Mercado de valores | United States of America | ||||||||
| Comisión por operación | 0% |
*Information provided by Capital.com
Johnson & Johnson ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Estadísticas clave
| Cierre previo* | 151.11 |
| Abrir* | 151 |
| Cambio de 1 año* | -13.18% |
| Rango del día* | 150.34 - 152.48 |
| Rango de 52 semanas | 150.11-186.69 |
| Volumen medio (10 días) | 9.33M |
| Volumen medio (3 meses) | 163.48M |
| Capitalización de mercado | 476.24B |
| Ratio P/E | 22.66 |
| Acciones en circulación | 3.12B |
| Ingresos | 94.94B |
| EPS | 6.74 |
| Dividendo (Rendimiento %) | 2.96102 |
| Beta | 0.53 |
| Próxima fecha de resultados | Apr 18, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Cierre | Change | Change (%) | Apertura | High | Low |
|---|---|---|---|---|---|---|
| Mar 24, 2023 | 152.36 | 1.50 | 0.99% | 150.86 | 152.61 | 150.26 |
| Mar 23, 2023 | 151.16 | -0.14 | -0.09% | 151.30 | 151.86 | 149.98 |
| Mar 22, 2023 | 151.07 | -2.31 | -1.51% | 153.38 | 154.35 | 150.86 |
| Mar 21, 2023 | 153.25 | -0.50 | -0.33% | 153.75 | 154.84 | 152.02 |
| Mar 20, 2023 | 153.48 | 2.23 | 1.47% | 151.25 | 153.91 | 151.25 |
| Mar 17, 2023 | 152.39 | -1.63 | -1.06% | 154.02 | 154.76 | 152.09 |
| Mar 16, 2023 | 153.71 | -0.67 | -0.43% | 154.38 | 154.56 | 152.46 |
| Mar 15, 2023 | 153.97 | 0.42 | 0.27% | 153.55 | 154.71 | 151.94 |
| Mar 14, 2023 | 153.11 | -1.36 | -0.88% | 154.47 | 155.15 | 151.73 |
| Mar 13, 2023 | 154.10 | 1.61 | 1.06% | 152.49 | 155.74 | 150.92 |
| Mar 10, 2023 | 151.38 | 0.37 | 0.25% | 151.01 | 153.33 | 150.36 |
| Mar 9, 2023 | 151.01 | -1.61 | -1.05% | 152.62 | 153.41 | 150.55 |
| Mar 8, 2023 | 152.36 | -1.59 | -1.03% | 153.95 | 154.64 | 152.32 |
| Mar 7, 2023 | 153.95 | -1.75 | -1.12% | 155.70 | 156.35 | 153.19 |
| Mar 6, 2023 | 155.55 | 1.59 | 1.03% | 153.96 | 155.56 | 153.96 |
| Mar 3, 2023 | 153.84 | 1.76 | 1.16% | 152.08 | 153.96 | 151.56 |
| Mar 2, 2023 | 152.07 | -0.09 | -0.06% | 152.16 | 152.61 | 151.07 |
| Mar 1, 2023 | 152.06 | -0.99 | -0.65% | 153.05 | 153.75 | 151.76 |
| Feb 28, 2023 | 153.15 | -2.26 | -1.45% | 155.41 | 155.79 | 152.85 |
| Feb 27, 2023 | 155.48 | -0.49 | -0.31% | 155.97 | 156.96 | 154.93 |
Johnson & Johnson Events
| Hora (UTC) (UTC) | País | Evento |
|---|---|---|
| Monday, April 17, 2023 | ||
| Hora (UTC) (UTC) 12:30 | País US
| Evento Q1 2023 Johnson & Johnson Earnings Release Q1 2023 Johnson & Johnson Earnings ReleaseForecast -Previous - |
| Friday, April 28, 2023 | ||
| Hora (UTC) (UTC) 14:00 | País US
| Evento Johnson & Johnson Annual Shareholders Meeting Johnson & Johnson Annual Shareholders MeetingForecast -Previous - |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Ingresos totales | 94943 | 93775 | 82584 | 82059 | 81581 |
| Ingresos | 94943 | 93775 | 82584 | 82059 | 81581 |
| Coste de los ingresos, total | 30989 | 29855 | 28327 | 27456 | 26986 |
| Beneficio bruto | 63954 | 63920 | 54257 | 54603 | 54595 |
| Gastos totales de explotación | 73218 | 70999 | 66087 | 64731 | 63582 |
| Gastos de venta/general/administración Gastos, total | 24765 | 24659 | 22084 | 22178 | 22540 |
| Investigación y desarrollo | 14603 | 14714 | 12159 | 11355 | 10775 |
| Gasto (ingreso) por intereses - Explotación neta | 814 | -370 | -410 | -183 | 394 |
| Gastos (ingresos) extraordinarios | 5004 | 4041 | 4428 | 1456 | 1826 |
| Other Operating Expenses, Total | -2957 | -1900 | -501 | 2469 | 1061 |
| Ingresos de explotación | 21725 | 22776 | 16497 | 17328 | 17999 |
| Ingresos netos antes de impuestos | 21725 | 22776 | 16497 | 17328 | 17999 |
| Ingresos netos después de impuestos | 17941 | 20878 | 14414 | 15119 | 15297 |
| Beneficio neto antes de partidas extra. Elementos | 17941 | 20878 | 14414 | 15119 | 15297 |
| Ingresos netos | 17941 | 20878 | 14714 | 15119 | 15297 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | 17941 | 20878 | 14414 | 15119 | 15297 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | 17941 | 20878 | 14714 | 15119 | 15297 |
| Beneficio neto diluido | 17941 | 20878 | 14714 | 15119 | 15297 |
| Promedio ponderado de acciones diluidas | 2663.9 | 2674 | 2670.7 | 2684.3 | 2728.7 |
| BPA diluido sin partidas extraordinarias | 6.73486 | 7.80778 | 5.39709 | 5.63238 | 5.60597 |
| Dividends per Share - Common Stock Primary Issue | 4.45 | 4.19 | 3.98 | 3.75 | 3.54 |
| BPA normalizado diluido | 8.67833 | 9.22111 | 6.98515 | 7.87 | 6.92185 |
| Total de partidas extraordinarias | 300 |
| Jan 2023 | Oct 2022 | Jul 2022 | Apr 2022 | Jan 2022 | |
|---|---|---|---|---|---|
| Ingresos totales | 23706 | 23791 | 24020 | 23426 | 24804 |
| Ingresos | 23706 | 23791 | 24020 | 23426 | 24804 |
| Coste de los ingresos, total | 7711 | 7794 | 7902 | 7582 | 7955 |
| Beneficio bruto | 15995 | 15997 | 16118 | 15844 | 16849 |
| Gastos totales de explotación | 19505 | 17969 | 18180 | 17564 | 19968 |
| Gastos de venta/general/administración Gastos, total | 6512 | 6089 | 6226 | 5938 | 7154 |
| Investigación y desarrollo | 3841 | 3597 | 3703 | 3462 | 4720 |
| Gasto (ingreso) por intereses - Explotación neta | -77 | 101 | 74 | 388 | -153 |
| Gastos (ingresos) extraordinarios | 1871.2 | 723 | 828 | 1382 | 1234 |
| Other Operating Expenses, Total | -353.2 | -335 | -553 | -1188 | -942 |
| Ingresos de explotación | 4201 | 5822 | 5840 | 5862 | 4836 |
| Ingresos netos antes de impuestos | 4201 | 5822 | 5840 | 5862 | 4836 |
| Ingresos netos después de impuestos | 3520 | 4458 | 4814 | 5149 | 4736 |
| Beneficio neto antes de partidas extra. Elementos | 3520 | 4458 | 4814 | 5149 | 4736 |
| Ingresos netos | 3520 | 4458 | 4814 | 5149 | 4736 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | 3520 | 4458 | 4814 | 5149 | 4736 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | 3520 | 4458 | 4814 | 5149 | 4736 |
| Beneficio neto diluido | 3520 | 4458 | 4814 | 5149 | 4736 |
| Promedio ponderado de acciones diluidas | 2653.1 | 2661.3 | 2667.9 | 2666.5 | 2672.2 |
| BPA diluido sin partidas extraordinarias | 1.32675 | 1.67512 | 1.80442 | 1.931 | 1.77232 |
| Dividends per Share - Common Stock Primary Issue | 1.13 | 1.13 | 1.13 | 1.06 | 1.06 |
| BPA normalizado diluido | 2.02302 | 1.94069 | 2.12204 | 2.41406 | 2.22457 |
- Anual
- Trimestral
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 60979 | 51237 | 45274 | 46033 | 43088 |
| Efectivo e inversiones a corto plazo | 31608 | 25185 | 19287 | 19687 | 18296 |
| Cash | 2936 | 2863 | 2637 | 2619 | 2929 |
| Efectivo y Equivalentes | 1901 | 2102 | 2864 | 3397 | 4288 |
| Inversiones a corto plazo | 26771 | 20220 | 13786 | 13671 | 11079 |
| Total deudores, neto | 15283 | 13576 | 14481 | 14098 | 13490 |
| Accounts Receivable - Trade, Net | 15283 | 13576 | 14481 | 14098 | 13490 |
| Total Inventory | 10387 | 9344 | 9020 | 8599 | 8765 |
| Prepaid Expenses | 3701 | 3132 | 2392 | 2699 | 2537 |
| Total Assets | 182018 | 174894 | 157728 | 152954 | 157303 |
| Property/Plant/Equipment, Total - Net | 19862 | 19766 | 18615 | 17035 | 17005 |
| Property/Plant/Equipment, Total - Gross | 48579 | 47804 | 44289 | 41851 | 41466 |
| Accumulated Depreciation, Total | -28717 | -28038 | -25674 | -24816 | -24461 |
| Goodwill, Net | 35246 | 36393 | 33639 | 30453 | 31906 |
| Intangibles, Net | 46392 | 53402 | 47643 | 47611 | 53228 |
| Other Long Term Assets, Total | 17655 | 12615 | 11409 | 11311 | 12076 |
| Total Current Liabilities | 45226 | 42493 | 35964 | 31230 | 30537 |
| Accounts Payable | 11055 | 9505 | 7537 | 7310 | |
| Accrued Expenses | 29293 | 28965 | 32496 | 20079 | 17467 |
| Notes Payable/Short Term Debt | 1635 | 832 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 2131 | 1799 | 1202 | 2297 | 3906 |
| Other Current Liabilities, Total | 1112 | 1392 | 2266 | 1317 | 1854 |
| Total Liabilities | 107995 | 111616 | 98257 | 93202 | 97143 |
| Total Long Term Debt | 29985 | 32635 | 26494 | 27684 | 30675 |
| Long Term Debt | 29985 | 32635 | 26494 | 27684 | 30675 |
| Deferred Income Tax | 7487 | 7214 | 5958 | 7506 | 8368 |
| Other Liabilities, Total | 25297 | 29274 | 29841 | 26782 | 27563 |
| Total Equity | 74023 | 63278 | 59471 | 59752 | 60160 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 3120 | 3120 | 3120 | 3120 | 3120 |
| Retained Earnings (Accumulated Deficit) | 123060 | 113890 | 110659 | 106216 | 101793 |
| Treasury Stock - Common | -39099 | -38490 | -38417 | -34362 | -31554 |
| Unrealized Gain (Loss) | -3 | 1 | 0 | 0 | 232 |
| Other Equity, Total | -13055 | -15243 | -15891 | -15222 | -13431 |
| Total Liabilities & Shareholders’ Equity | 182018 | 174894 | 157728 | 152954 | 157303 |
| Total Common Shares Outstanding | 2628.97 | 2632.51 | 2632.51 | 2662.32 | 2682.52 |
| Other Current Assets, Total | 0 | 94 | 950 | ||
| Long Term Investments | 1884 | 1481 | 1148 | 511 |
| Apr 2022 | Jan 2022 | Oct 2021 | Jul 2021 | Apr 2021 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 60424 | 60979 | 59889 | 53769 | 52533 |
| Efectivo e inversiones a corto plazo | 30388 | 31608 | 31001 | 25306 | 24619 |
| Cash | 3128 | 2936 | 2607 | 2313 | 2247 |
| Efectivo y Equivalentes | 1579 | 1901 | 2120 | 2618 | 2094 |
| Inversiones a corto plazo | 25681 | 26771 | 26274 | 20375 | 20278 |
| Total deudores, neto | 15594 | 15283 | 14911 | 14871 | 14938 |
| Accounts Receivable - Trade, Net | 15594 | 15283 | 14911 | 14871 | 14938 |
| Total Inventory | 10990 | 10387 | 10387 | 10100 | 9952 |
| Prepaid Expenses | 3452 | 3701 | 3590 | 3492 | 3024 |
| Total Assets | 178355 | 182018 | 179228 | 176440 | 172557 |
| Property/Plant/Equipment, Total - Net | 18701 | 19862 | 18478 | 18632 | 18367 |
| Property/Plant/Equipment, Total - Gross | 47702 | 47679 | 47347 | 47201 | 46430 |
| Accumulated Depreciation, Total | -29001 | -28717 | -28869 | -28569 | -28063 |
| Goodwill, Net | 34935 | 35246 | 35569 | 35819 | 35688 |
| Intangibles, Net | 44420 | 46392 | 47776 | 50244 | 51110 |
| Long Term Investments | 1452 | 1884 | 1867 | 1678 | 1452 |
| Other Long Term Assets, Total | 18423 | 17655 | 15649 | 16298 | 13407 |
| Total Current Liabilities | 43390 | 45226 | 44561 | 38721 | 40932 |
| Accounts Payable | 9309 | 11055 | 8961 | 8704 | 8503 |
| Accrued Expenses | 28076 | 29293 | 29641 | 25644 | 27202 |
| Notes Payable/Short Term Debt | 3800 | 1635 | 1300 | 600 | 300 |
| Current Port. of LT Debt/Capital Leases | 497 | 2131 | 2498 | 2573 | 3050 |
| Other Current Liabilities, Total | 1708 | 1112 | 2161 | 1200 | 1877 |
| Total Liabilities | 103646 | 107995 | 108956 | 106860 | 106723 |
| Total Long Term Debt | 28851 | 29985 | 30130 | 30310 | 30263 |
| Long Term Debt | 28851 | 29985 | 30130 | 30310 | 30263 |
| Deferred Income Tax | 6424 | 7487 | 7147 | 9016 | 6507 |
| Other Liabilities, Total | 24981 | 25297 | 27118 | 28813 | 29021 |
| Total Equity | 74709 | 74023 | 70272 | 69580 | 65834 |
| Common Stock | 3120 | 3120 | 3120 | 3120 | 3120 |
| Retained Earnings (Accumulated Deficit) | 124380 | 123060 | 121092 | 120154 | 116508 |
| Treasury Stock - Common | -39034 | -39099 | -38525 | -38594 | -38466 |
| Unrealized Gain (Loss) | -16 | -3 | 0 | 0 | 1 |
| Other Equity, Total | -13741 | -13055 | -15415 | -15100 | -15329 |
| Total Liabilities & Shareholders’ Equity | 178355 | 182018 | 179228 | 176440 | 172557 |
| Total Common Shares Outstanding | 2629.38 | 2628.97 | 2632.49 | 2631.99 | 2632.7 |
| Preferred Stock - Non Redeemable, Net | 0 |
- Anual
- Trimestral
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Ingresos netos/Línea de salida | 20878 | 14714 | 15119 | 15297 | 1300 |
| Efectivo de actividades de explotación | 23410 | 23536 | 23416 | 22201 | 21056 |
| Efectivo de actividades de explotación | 7390 | 7231 | 7009 | 6929 | 5642 |
| Deferred Taxes | -2079 | -1141 | -2476 | -1016 | 2406 |
| Partidas no monetarias | 1459 | 42 | -101 | 988 | 467 |
| Cash Taxes Paid | 4768 | 4619 | 4191 | 4570 | 3312 |
| Intereses pagados en efectivo | 990 | 904 | 995 | 1049 | 960 |
| Cambios en el capital circulante | -4238 | 2690 | 3865 | 3 | 11241 |
| Efectivo de actividades de inversión | -8683 | -20825 | -6194 | -3167 | -14868 |
| Gastos de capital | -3652 | -3347 | -3498 | -3670 | -3279 |
| Otras partidas de flujo de caja de inversión, total | -5031 | -17478 | -2696 | 503 | -11589 |
| Efectivo procedente de actividades de financiación | -14047 | -6120 | -18015 | -18510 | -7673 |
| Elementos de flujo de caja de financiación | 395 | -627 | 575 | -148 | -188 |
| Total Cash Dividends Paid | -11032 | -10481 | -9917 | -9494 | -8943 |
| Emisión (retiro) de acciones, neto | -2420 | -2107 | -5792 | -4919 | -5296 |
| Emisión (amortización) de deuda, neta | -990 | 7095 | -2881 | -3949 | 6754 |
| Efectos del cambio de divisas | -178 | 89 | -9 | -241 | 337 |
| Variación neta de la tesorería | 502 | -3320 | -802 | 283 | -1148 |
| Apr 2022 | Jan 2022 | Oct 2021 | Jul 2021 | Apr 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 5149 | 20878 | 16142 | 12475 | 6197 |
| Cash From Operating Activities | 3979 | 23410 | 17678 | 9388 | 4074 |
| Cash From Operating Activities | 1769 | 7390 | 5547 | 3733 | 1894 |
| Deferred Taxes | -926 | -2079 | -2564 | -685 | -730 |
| Non-Cash Items | 726 | 1459 | 1223 | 34 | -272 |
| Changes in Working Capital | -2739 | -4238 | -2670 | -6169 | -3015 |
| Cash From Investing Activities | -3634 | -8683 | -3323 | -604 | -185 |
| Capital Expenditures | -607 | -3652 | -2237 | -1490 | -677 |
| Other Investing Cash Flow Items, Total | -3027 | -5031 | -1086 | 886 | 492 |
| Cash From Financing Activities | -4385 | -14047 | -10611 | -8404 | -5125 |
| Financing Cash Flow Items | -373 | 395 | 269 | 213 | 188 |
| Total Cash Dividends Paid | -2787 | -11032 | -8241 | -5450 | -2659 |
| Issuance (Retirement) of Stock, Net | -1256 | -2420 | -1652 | -1526 | -1202 |
| Issuance (Retirement) of Debt, Net | 31 | -990 | -987 | -1641 | -1452 |
| Foreign Exchange Effects | 16 | -178 | -125 | -33 | -78 |
| Net Change in Cash | -4024 | 502 | 3619 | 347 | -1314 |
| Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
|---|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 7.8771 | 245753287 | 1454228 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.5542 | 142084378 | 198067 | 2022-12-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.0211 | 125452825 | -986275 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.5372 | 47958583 | 294671 | 2022-12-31 | LOW |
| State Farm Insurance Companies | Insurance Company | 1.0153 | 31675492 | 0 | 2022-12-31 | LOW |
| Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 0.861 | 26861119 | -1125820 | 2022-12-31 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.8364 | 26093398 | 1700287 | 2022-12-31 | LOW |
| T. Rowe Price Associates, Inc. | Investment Advisor | 0.8236 | 25695612 | 3814698 | 2022-12-31 | LOW |
| Morgan Stanley Smith Barney LLC | Investment Advisor | 0.7267 | 22671643 | 204861 | 2022-12-31 | LOW |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7015 | 21884954 | 24625 | 2022-12-31 | LOW |
| MFS Investment Management | Investment Advisor/Hedge Fund | 0.6562 | 20472848 | -1558866 | 2022-12-31 | LOW |
| BofA Global Research (US) | Research Firm | 0.6347 | 19800227 | -625991 | 2022-12-31 | LOW |
| Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.5901 | 18410390 | -654505 | 2022-12-31 | LOW |
| BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.5892 | 18382540 | 418336 | 2022-12-31 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 0.586 | 18280864 | 141119 | 2022-12-31 | LOW |
| Capital International Investors | Investment Advisor | 0.5632 | 17569654 | -1212751 | 2022-12-31 | LOW |
| Charles Schwab Investment Management, Inc. | Investment Advisor | 0.5477 | 17086571 | 174516 | 2022-12-31 | LOW |
| Wells Fargo Advisors | Research Firm | 0.5436 | 16958793 | 47687 | 2022-12-31 | LOW |
| Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 0.532 | 16596744 | -2192644 | 2022-12-31 | LOW |
| BlackRock Asset Management Ireland Limited | Investment Advisor | 0.4993 | 15576114 | -481392 | 2022-12-31 | LOW |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group500K+
Traders
92K+
Clientes activos mensualmente
$53M+
Volumen mensual de inversión
$30M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
Comisión de la operación
0
- 1:1
Apalancamiento
1:1
- 20
- 100
- 500
- 1000
- 10000
Inversión
Tamaño de la operación (Apalancamiento x Inversión)
Apertura
Cierre
En corto En largo
Johnson & Johnson Company profile
Sobre Johnson & Johnson
Johnson & Johnson es un holding que se dedica a la investigación y desarrollo, fabricación y venta de una gama de productos en el campo de la salud. Opera a través de tres segmentos: consumidor, farmacéutico y dispositivos médicos. Su enfoque principal son los productos relacionados con la salud y el bienestar humanos. El segmento de consumidores incluye una gama de productos utilizados en los mercados de cuidado de bebés, cuidado bucal, cuidado de la piel, farmacéutico sin receta médica, salud de la mujer y cuidado de heridas. El segmento farmacéutico se centra en cinco áreas terapéuticas, que incluyen inmunología, enfermedades infecciosas, neurociencia, oncología y enfermedades cardiovasculares y metabólicas. El segmento de Dispositivos médicos incluye una gama de productos utilizados en los campos de ortopedia, cirugía, cardiovascular, cuidado de la diabetes y cuidado de la vista. Sus instalaciones de investigación se encuentran en los Estados Unidos, Bélgica, Brasil, Canadá, China, Francia, Alemania, India, Israel, Japón, los Países Bajos, Singapur, Suiza y el Reino Unido.
- IndustriaPharmaceuticals (NEC)
- DirecciónOne Johnson & Johnson Plaza, NEW BRUNSWICK, NJ, United States (USA)
- Empleados141700
- CEOAlex Gorsky
| Industry: | Pharmaceuticals (NEC) |
One Johnson & Johnson Plaza
NEW BRUNSWICK
NEW JERSEY 08933
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 500.000 traders de todo el mundo que eligen operar con Capital.com